tbuckley/cabot-search huggingface dataset:
Abstract 739: The role of obesity on inflammation markers in the prostate tumor microenvironment
Authors: Charnita M. Zeigler-Johnson, Knashawn H. Morales, Priti Lal, Timothy R. Rebbeck, Michael Feldman
Journal: Cancer Research (2016)

Abstract Background: Obesity reflects a chronic inflammatory environment that may contribute to prostate cancer progression and poor treatment outcomes. However, it is not clear which mechanisms drive this association within the tumor microenvironment. The aim of this pilot study was to examine prostatic inflammation via tumor infiltrating lymphocytes and macrophages characterized by obesity and cancer severity. Methods: We studied paraffin-embedded prostatectomy tissue from 99 participants (63 non-obese and 36 obese) from the Study of Clinical Outcomes, Risk and Ethnicity (University of Pennsylvania) Pathologists analyzed the tissue for type and count of lymphocytes and macrophages, including CD3, CD8, FOXP3, and CD68. Pathology data were linked to clinical and demographic variables. Statistical analyses included frequency tables, Kruskal-Wallis tests, Spearman correlations, and multivariable models. Results: We observed positive univariate associations between the number of CD68 cells and tumor grade (p = 0.019), as well as biochemical failure (p = 0.033). In multivariable analysis, CD3 and CD8 counts were associated with time to biochemical failure (HR = 0.93, 95% CI = 0.88-0.99; HR = 1.08, 95% CI = 1.01-1.17, respectively.) Preliminary results suggested differences in lymphocytes by race. There were no differences in lymphocytes or macrophages by obesity status or BMI. Conclusions: The number of lymphocytes and macrophages in the tumor microenvironment did not differ by obesity status. However, these inflammation markers were associated with poor prostate cancer outcomes. Further examination of underlying mechanisms that influence obesity-related effects on prostate cancer outcomes is warranted. Such research will guide immunotherapy protocols and weight management as they apply to diverse patient populations and phenotypes. Citation Format: Charnita M. Zeigler-Johnson, Knashawn H. Morales, Priti Lal, Timothy R. Rebbeck, Michael Feldman. The role of obesity on inflammation markers in the prostate tumor microenvironment. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 739.
Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS)
Authors: Maria Guadalupe Rodriguez-Gonzalez, Yaneth Martinez-Ibarra, Jorge Vela-Ojeda, Kevin Nacho-Vargas, Luis Meillon, Yamile Fattel, Julio Robledo, Tonatiuh Romero-Salas, Moises Xolotl-Castillo
Journal: Blood (2013)
Abstract 5284: Characterizing the differences of allelic imbalance between tumor and normal tissues by next-generation sequencing
Authors: Yao-Wei Jheng, Yu-Chiao Chiu, Tzu-Pin Lu, Liang-Chuan Lai, Mong-Hsun Tsai, Tzu-Hung Hsiao, Eric Y Chuang
Journal: Cancer Research (2016)

Abstract Genetic variation has proved to contribute to tumor formation. One of the phenomenon caused by genetic variation, allelic imbalance, means different expression abundance between two alleles, recently has become a special landmark on cancer biology, with high prevalence in recent cancer studies. However, the present of allelic imbalance has not been fully understood yet. Taking the advantages of next generation sequencing, allelic imbalance can be identified and quantified through bioinformatics algorithms. Here, we developed a mathematical model to identify with allelic imbalance by concurrently analyzing RNA-Seq and DNA-Seq. First we called heterozygous SNP variants from both RNA-Seq and Exome-Seq data. The allele ratio is counted by the ratio of read depth between two alleles after integrating SNPs into gene level. Next, we identify allelic imbalance genes by differences of RNA and DNA allele ratios between tumor and normal samples. As results, a total of 91143 SNPs were identified in Exome-Seq, and about 3% (2586 out of 91143) SNPs were heterozygous in both tumor and normal tissues. We found that about 118 allelic imbalance genes in tumor tissue are significantly different from those in normal tissue. Furthermore, we investigate the enriched function of these allelic imbalance genes. These result showed that these genes are significantly enriched in DNA repair pathway. We speculated that allelic imbalance in tumor tissue may be involved in the dysregulation of DNA repair. Also other enriched functions were identified, such as z-finger protein pathway. Our goal is to investigate the landscape of allelic imbalance between tumor sample and normal sample. Our results demonstrate the role of allelic imbalance of dysregulation of tumor. Moreover, our method can be applied to uncover more basic mechanisms on allelic imbalance and tumorigenesis. Citation Format: Yao-Wei Jheng, Yu-Chiao Chiu, Tzu-Pin Lu, Liang-Chuan Lai, Mong-Hsun Tsai, Tzu-Hung Hsiao, Eric Y Chuang. Characterizing the differences of allelic imbalance between tumor and normal tissues by next-generation sequencing. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5284.
Abstract 1704: High mobility group A1 chromatin remodeling protein expands the intestinal stem cell compartment and Paneth cell niche through Wnt/β-catenin signaling and Sox9
Authors: Lingling Xian, Tait Huso, Amy Belton, David Huso, Linda M. S. Resar.
Journal: Cancer Research (2016)

Abstract The High Mobility Group A1 (HMGA1) gene is overexpressed in most poorly differentiated cancers and high levels portend adverse clinical outcomes, although the molecular mechanisms through which it functions are poorly understood. HMGA1 encodes the HMGA1a and HMGA1b chromatin remodeling proteins, which modulate gene expression by bending chromatin and orchestrating the assembly of transcription factor complexes to DNA. HMGA1 is highly expressed during embryogenesis, but silenced in adult, differentiated tissues. Postnatally, HMGA1 expression is maintained in adult stem cells, such as intestinal stem cells (ISCs); however, its role in this setting has been unknown. Here, we report that Hmga1 overexpression in ISCs of transgenic mice drives expansion in the ISC compartment leading to hyperproliferation, aberrant crypt formation, and polyposis. Surprisingly, Hmga1 transgenic mice also exhibit marked expansion in terminally differentiated Paneth cells, which comprise an epithelial cell niche for ISCs. To dissect the mechanisms mediating these phenotypes, we generated three-dimensional (3D) intestinal organoids with varied expression of Hmga1. Strikingly, silencing Hmga1 in wildtype crypt cells disrupts their ability to organize into functional 3D organoids with bud formation, while crypt cells expressing ectopic Hmga1 exhibit enhanced organoid formation with increased ISC number, proliferation, and bud development. Because Wnt/β-catenin signaling is central to ISC function, we determined whether Hmga1 modulates this pathway. β-catenin protein is increased in the crypts of the Hmga1 transgenic mice and organoids. Hmga1 amplifies Wnt/β-catenin signaling by inducing both genes that encode Wnt cell surface receptors and target genes downstream of Wnt/β-catenin. Hmga1 also directly up-regulates Sox9, which is required for terminal differentiation to Paneth cells. This is the first example of Hmga1 fostering terminal differentiation to establish a stem cell niche. In human intestinal epithelium, HMGA1 and SOX9 are highly correlated (P = 0.008), and both become up-regulated in carcinogenesis. These results reveal a novel role for Hmga1 in intestinal homeostasis by maintaining both the stem cell pool and epithelial niche compartment and suggest that deregulated Hmga1 perturbs this equilibrium during intestinal carcinogenesis. Citation Format: Lingling Xian, Tait Huso, Amy Belton, David Huso, Linda M. S. Resar. High mobility group A1 chromatin remodeling protein expands the intestinal stem cell compartment and Paneth cell niche through Wnt/β-catenin signaling and Sox9. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1704.
Abstract 1573: miR-Test: a blood test for lung cancer early detection
Authors: Francesca Montani, Matteo Jacopo Marzi, Fabio Dezi, Elisa Dama, Rose Mary Carletti, Giuseppina Bonizzi, Raffaella Bertolotti, Massimo Bellomi, Cristiano Rampinelli, Patrick Maisonneuve, Lorenzo Spaggiari, Giulia Veronesi, Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi
Journal: Cancer Research (2015)

Abstract Background: Lung cancer is the leading cause of cancer death worldwide. As lung cancer is asymptomatic in its early stages, the majority of patients are diagnosed with advanced disease, when the tumor is unresectable. Consequently, the survival rate is very low: 15% at 5 years. It is vital, therefore, that screening programs and novel diagnostic tools are developed, which will increase the detection of lung cancer in its early stages (stage I-II), when the tumor is still curable, to reduce lung cancer mortality. Recently, we described a serum microRNA signature diagnostic for asymptomatic, early stage, lung cancer. The availability of reliable biomarkers to identify high-risk individuals might help to reduce the size of the target population for LDCT-based programs, thereby reducing costs and probably increasing compliance Methods: We performed a large-scale validation study of a miRNA blood test based on our signature (the miR-Test) in a population of high-risk individuals (N = 1115) enrolled in the lung cancer screening program COSMOS (Continuous Observation of SMOking Subjects), and other 74 lung cancer patients diagnosed outside of screening. Results: The miR-Test showed overall accuracy, specificity and sensitivity of 75%, 78%, and 75%, respectively, with an AUC of 0.85. The test appears to have a dual origin: the first from epithelial cells (the epithelial-like component); the second from cells of hematopoietic origin (the inflammatory-like component). Of note, we found that both components are needed to maintain a good performance of the miR-Test. Conclusions: The relatively high sensitivity of the miR-Test in detecting asymptomatic lung cancer and its high negative predictive value (NPV &amp;gt; 99%), confirm the effectiveness of the test, both interms of its ability to identify asymptomatic lung cancer patients and to reduce significantly unnecessary CTs on healthy individuals. Citation Format: Francesca Montani, Matteo Jacopo Marzi, Fabio Dezi, Elisa Dama, Rose Mary Carletti, Giuseppina Bonizzi, Raffaella Bertolotti, Massimo Bellomi, Cristiano Rampinelli, Patrick Maisonneuve, Lorenzo Spaggiari, Giulia Veronesi, Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi. miR-Test: a blood test for lung cancer early detection. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1573. doi:10.1158/1538-7445.AM2015-1573
PR1-Specific T Cell Responses in the First Months Following T-Cell Depleted Allogeneic Stem Cell Transplantation Occur in Both Myeloid and Non-Myeloid Malignancies but Are Only Associated with a GVL Effect in Myeloid Leukemias.
Authors: Katayoun Rezvani, Yong Agnes, Rhoda B. Eniafe, Stephan Mielke, Bipin N. Savani, David A. Price, Emma Gostick, Daniel C. Douek, John M. Goldman, A. John Barrett
Journal: Blood (2006)
Abstract 2745: A genetic screen to identify tumor suppressive DDR genes in breast cancer
Authors: Katerina D. Fagan-Solis, Gaorav P. Gupta
Journal: Cancer Research (2016)

Abstract To maintain genomic integrity, cells utilize a DNA damage response (DDR) mechanism that 1) functions to repair damaged DNA efficiently and 2) commits cells to apoptosis if damage is irreparable. Failure of this mechanism results in genomic instability and cancer predisposition. Defects in DDR have been implicated in both sporadic and familial breast and ovarian cancer predisposition syndromes (e.g. BRCA1, BRCA2, and PALB2), although the specific pathway components that are disrupted have not been elucidated. In particular, an impaired DDR may contribute to the pathophysiology of triple-negative (ER-/PR-/HER2-) breast cancer (TNBC) due to the extent and complexity of the genomic instability that is observed. We identified the DNA damage sensing Mre11- Rad50-Nbs1 (MRN) complex as an essential mediator of the oncogene-induced DDR. Disrupting the MRN complex in mouse models promotes the development of genomically unstable, metastatic breast cancer. The clinical relevance of this pathway is highlighted by the observation that components of the Mre11 complex are perturbed in a significant fraction of human TNBCs, which correlates with clinical outcomes. However, lack of MRN suppression in a majority of TNBCs indicates that alternative DDR components may also be inactivated to promote breast cancer development. Our goal is to identify additional DDR genes that, when perturbed, promote the development of genomically unstable breast cancers. In order to accurately distinguish driver genes from bystander genes we have developed a platform to identify DDR genes that mediate oncogene-induced senescence in mammary epithelial cells using both shRNA and CRISPR pooled libraries. Analysis of newly identified tumor suppressor genes, compared to what is already known about Mre11 and p53 (positive controls), will enable us to determine causality of specific DDR mutations in breast cancer development and importantly, the genomic instability phenotype that is typical for TNBC. The insights gleaned from this study may ultimately provide the means to determine the optimal treatment regimen for each patient with TNBC, and to prevent over-treatment of patients where certain chemotherapies may not be effective. Citation Format: Katerina D. Fagan-Solis, Gaorav P. Gupta. A genetic screen to identify tumor suppressive DDR genes in breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2745.
Abstract 954: Analysis of noncoding RNA expression in a mouse model of PTEN-deficient prostate cancer
Authors: Marco A. De Velasco, Yurie Kura, Kazuko Sakai, Yuji Hatanaka, Yoshihiko Fujita, Yosuke Togashi, Masato Terashima, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura
Journal: Cancer Research (2016)

Abstract Prostate cancer is a heterogeneous disease that is driven by combined genetic and epigenetic alterations. A significant portion of the mammalian genome consists of non-coding regions of RNA. Increasing evidence has shown that these noncoding RNAs (ncRNAs) have significant roles in the epigenetic regulation of several cellular processes, and their dysregulation can contribute to tumorigenesis and promote disease progression in many cancer types. In order to gain better insights into the potential roles of ncRNAs in prostate cancer, we used a genetically engineered mouse model of prostate cancer to perform a comparative analysis of the cancer transcriptome and the landscape of ncRNAs in castration-naïve prostate tumors and the progression to castration-resistant disease. Whole transcription arrays were used to explore both messenger (mRNA) and long intergenic non-coding RNA (LincRNA) transcript expression in normal prostate tissue from wildtype mice and prostate tumors from conditional PTEN-knockout mice. Comparative analyses were performed between prostate tumor samples from castration-naïve mice and, at 4 weeks and 10 weeks post-surgical castration. Altered expression of ncRNAs was most commonly observed and accounted for 56.2% (2370/4216), 47.6% (4460/9366) and 41.57% (1545/3717) of the total genes differentially expressed between normal mouse prostate and prostate tumors from castration-naïve, 4 weeks post-castration and 10 weeks post-castration, respectively. We also profile the expression of relevant cancer-related lincRNAs present in these models. Overall, our analyses provide data to support a role of LincRNA dysregulation in the pathogenesis of PTEN-deficient prostate cancer, and suggest that these mouse models might provide a potential preclinical tool to test candidate prospective therapies targeting ncRNAs. Citation Format: Marco A. De Velasco, Yurie Kura, Kazuko Sakai, Yuji Hatanaka, Yoshihiko Fujita, Yosuke Togashi, Masato Terashima, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Analysis of noncoding RNA expression in a mouse model of PTEN-deficient prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 954.
Abstract 1651: Overexpression of hepatoma upregulated protein (HURP) promotes radioresistance in prostate cancer cells
Authors: Mohamed Hassan, Abdelouahid El Khattouti, Tangeng Ma, Ingrid Espinoza, W. Andrew Day, Srinivasan Vijayakumar, Christian R. Gomez
Journal: Cancer Research (2016)

Abstract Despite progression in diagnosis and treatment, prostate cancer (PCa) still represents major cause of cancer-related mortality and morbidity in men. Although radiation therapy offers clinical benefit over other therapeutic modalities, the success of this therapeutic modality is commonly hampered by significant resistance in advanced tumor. So far, the mechanisms governing the acquired resistance to radiotherapy have not been discussed in detail. Hepatoma Up-Regulated Protein (HURP) is a cell cycle-regulated and microtubule-associated protein. It functions as a Ran GTPase effector and is involved in the stabilization of the mitotic kinetochore fibers. The expression of this protein is elevated in different tumor types and associated with tumor progression and aggressiveness. We recently reported on the value of HURP as an independent prognostic factor for high-risk PCa. The aim of this study was to address the role of HURP in the modulation of PCa resistance to γ- irradiation. Cell lines (LNCaP, PC3, and DU145) with regulated expression of HURP protein using a Lent viral Tet-On 3G Inducible Expression System were irradiated using a Cs-137 γ-source. Overexpression of HURP suppressed γ- irradiation- induced apoptosis. This suppression was associated with the expression of E2F1, p53, p21 together with the phosphorylation of apoptosis signal-regulating kinase1 (ASK1), c-jun-N-terminal kinase (JNK) and Ataxia-telangiectasia mutated (ATM) and histone family member X (H2AX). Also, inhibition of γ- irradiation- induced- cytochrome c release, cleavage of caspase-9, caspase-3, PARP, and reactive oxygen species (ROS) was noted. The observed resistance was consequence of HURP's ability to trigger the ubiquitination of p53 and ATM that, in turn, resulted in the inhibition of downstream pathways, which are essential for the modulation of γ- irradiation-induced apoptosis. Our data provide evidence for the involvement of HURP in the modulation of PCa cell resistance to γ-irradiation via a mechanism mediated by ubiquitination of ATM and p53. Understanding of the biological mechanisms underlying HURP-mediated resistance of PCa to available therapies may help to improve the treatment strategy and emphasize HURP as therapeutic target for PCa treatment. Funding sources: Department of Defense Grant PC094680 and Prostate Cancer Foundation Creativity Award. Citation Format: Mohamed Hassan, Abdelouahid El Khattouti, Tangeng Ma, Ingrid Espinoza, W. Andrew Day, Srinivasan Vijayakumar, Christian R. Gomez. Overexpression of hepatoma upregulated protein (HURP) promotes radioresistance in prostate cancer cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1651.
NHS trust may shut emergency department at night because of staffing “crisis”
Authors: Gareth Iacobucci
Journal: BMJ (2016)

An NHS hospital trust is considering closing its emergency department at night owing to a chronic shortage of staff.

United Lincolnshire Hospitals NHS Trust (ULHT) said that it had reached “crisis point” and warned that patient safety could be at risk if it did not take drastic action at Grantham and District Hospital.

The trust, which runs three emergency departments in Lincolnshire, said that it had been “seriously affected” by a national shortage of emergency medicine doctors and did not have enough medical staff to fill shifts in three departments 24 hours a day, seven days a week.

After considering its options the trust said that it may close Grantham’s emergency department at night, as the hospital had …
Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party
Authors: Birte Friedrichs, Andre Tichelli, Andrea Bacigalupo, Nigel H. Russell, Tapani Ruutu, Meral Beksac, Gerard Socie, Norbert Schmitz
Journal: Blood (2008)
Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes
Authors: Laura F Newell, Shernan G. Holtan, Jason Rosenzweig, Jane Yates, Michael Garbati, R. K. Rathbun, Winifred Keeble, Jeffrey W. Tyner, Irina Burd, Grover C. Bagby
Journal: Blood (2015)
Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival Mechanisms
Authors: Stefan Burén, Ana L. Gomes, Ana Teijeiro, Mohamad-Ali Fawal, Mahmut Yilmaz, Krishna S. Tummala, Manuel Perez, Manuel Rodriguez-Justo, Ramón Campos-Olivas, Diego Megías, Nabil Djouder
Journal: Cancer Cell (2016)